<DOC>
	<DOCNO>NCT02875223</DOCNO>
	<brief_summary>Study CC-90011-ST-001 open-label , Phase 1 , dose escalation expansion , First-In-Human ( FIH ) clinical study CC-90011 subject relapse and/or refractory solid tumor ( include neuroendocrine carcinoma ( NEC ) ) Non-Hodgkin 's lymphoma ( NHLs ) . The dose escalation part ( Part A ) study explore escalate oral dos CC-90011 estimate maximum tolerate dose ( MTD ) CC-90011 .</brief_summary>
	<brief_title>A Safety Efficacy Study CC-90011 Subjects With Relapsed and/or Refractory Solid Tumors Non-Hodgkin 's Lymphomas</brief_title>
	<detailed_description>Parts A B consist 3 period : Screening , Treatment Follow-up . Screening Period The Screening Period start 28 day ( ± 3 day ) prior first dose CC-90011 . The informed consent document ( ICD ) must sign date subject administer staff prior start study procedure . All screen test procedure must complete within 28 day ( ±3 day ) prior first dose CC-90011 . Treatment Period During Treatment Period , CC-90011 initially administer orally 4-week ( 28 day ) Cycle . Follow-up Period In Follow-up Period , subject follow 28 day ( ± 3 day ) last dose CC-90011 safety . After Safety Follow-up visit , subject follow every subsequent 3 month ( ± 2 week ) survival follow-up 2 year death , lose follow-up , End Trial , whichever occur first .</detailed_description>
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Lymphoma , Non-Hodgkin</mesh_term>
	<criteria>Subjects must satisfy follow criterion enrol study : ≥ 18 year age Subjects histological cytological confirmation advance unresectable solid tumor ( include small cell lung cancer ( SCLC ) neuroendocrine carcinoma ( NEC ) ) NonHodgkin 's lymphoma ( NHL ) ( diffuse large Bcell lymphoma ( DLBCL ) indolent NonHodgkin 's lymphoma ( iNHL ) The presence follow exclude subject enrollment : 1. low grade ( G1 ) neuroendocrine tumor ( ≤ 2 per high power field ( HPF ) and/or ≤ 2 % Ki67 index ) carcinoid exclude . 2 . Subject receive anticancer therapy ( either approve investigational ) ≤ 4 week 5 halflives , whichever short , prior signing ICD . &lt; 42 day prior nitrosureas mitomycin C 3 . Toxicities result prior systemic cancer therapy must resolve ≤National Cancer Institute ( NCI ) Common Terminology Criteria Adverse Events ( CTCAE ) Grade 1 prior start CC90011 treatment ( exception grade 2 peripheral neuropathy alopecia ) . 4 . Prior ASCT ≤ 3 month first dose recover . 5 . Prior allogeneic stem cell transplant either standard reduce intensity conditioning . 6 . Subject undergone major surgery ≤ 4 week minor surgery ≤ 2 week prior sign ICD recover surgery . 7 . Subject complete radiation treatment &lt; 4 week prior sign ICD &lt; 2 week palliative bone radiotherapy ( single fraction ) . Subjects &gt; 25 % myelopoetic BM radiation allow enrol study . 8 . Subject persistent diarrhea due malabsorptive syndrome ( celiac sprue inflammatory bowel disease ) ≥ NCI CTCAE Grade 2 , despite medical management ) , significant GI disorder could affect absorption CC90011 . 9 . Subject symptomatic uncontrolled ulcer ( gastric duodenal ) , particularly history and/or risk perforation GI tract hemorrhage . 10 . Subject hemorrhage/bleeding event &gt; CTCAE Grade 2 haemoptysis &gt; 1 teaspoon within 4 week prior first dose 11 . Symptomatic untreated unstable central nervous system ( CNS ) metastases per protocol . 12 . Subject SCLC history interstitial lung disease ( ILD ) OR history pneumonitis require oral Intra Venous ( IV ) steroids 13 . Subject know symptomatic acute chronic pancreatitis . 14 . Subject impaired cardiac function clinically significant cardiac disease , per protocol . 15 . Subject clinically significant heart disease congestive heart failure require treatment uncontrolled hypertension ( blood pressure ≥ 160/95 mm Hg ) . 16 . Subject pregnant nursing female . 17 . Subject know Human immunodeficiency virus ( HIV ) infection . 18 . Subject know chronic active hepatitis B C virus ( HBV , HCV ) infection . 19 . Subject ongoing treatment chronic , therapeutic dosing anticoagulant ( eg , warfarin , low molecular weight heparin , Factor Xa inhibitor , thrombin antagonist ) . Low dose low molecular weight heparin catheter maintenance shortterm prophylaxis subject prior PE DVT permit careful consideration Investigator . 20 . Subject history concurrent second cancer require active , ongoing systemic treatment . 21 . Subject significant medical condition ( eg , active uncontrolled infection renal disease ) , laboratory abnormality , psychiatric illness would prevent subject participate ( compromise compliance ) study would place subject unacceptable risk he/she participate study . 22 . Subject condition confounds ability interpret data study .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2016</verification_date>
	<keyword>Safety</keyword>
	<keyword>CC-90011</keyword>
	<keyword>Relapsed and/or Refractory Solid Tumors</keyword>
	<keyword>Non-Hodgkin 's Lymphomas</keyword>
</DOC>